Therefore, clinical guidelines in general discourage from testing for BRCA2 mutations in persons below age 18, given that screening for breast cancer in BRCA2 carriers (e.g. MRI scans of the breast) is generally only offered at age 25 and older [45, 46]. This evidence concerns the gene BRCA2 and breast cancer.